Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EMMALIND APONTE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1699985002
CMS profile
895385
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,364.35

107 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,337.69 105
Education $26.66 2

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EMMALIND APONTE

NPI 1699985002 · CMS profile ID 895385

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699985002?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699985002?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699985002?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1699985002?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

107 matching records · $2,364.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 107 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 107.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $13.2912/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658307407 CMS
AstraZeneca Pharmaceuticals LP $19.7312/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685745281 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.9512/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700053459 CMS
E.R. Squibb & Sons, L.L.C. $9.8111/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300847 CMS
Janssen Biotech, Inc. $7.6611/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658307403 CMS
Alexion Pharmaceuticals, Inc. $11.8811/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695597125 CMS
E.R. Squibb & Sons, L.L.C. $10.2711/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300843 CMS
Janssen Biotech, Inc. $15.5411/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658307399 CMS
Novartis Pharmaceuticals Corporation $16.7311/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658919905 CMS
AbbVie, Inc. $23.0511/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647803755 CMS
E.R. Squibb & Sons, L.L.C. $10.1011/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300837 CMS
Novartis Pharmaceuticals Corporation $20.4311/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658919931 CMS
AstraZeneca Pharmaceuticals LP $81.0710/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685097061 CMS
AbbVie, Inc. $15.9810/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647803745 CMS
E.R. Squibb & Sons, L.L.C. $12.6310/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300835 CMS
PFIZER INC. $90.2710/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673190719 CMS
AbbVie, Inc. $19.6610/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647803727 CMS
Merck Sharp & Dohme Corporation $13.5810/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695789311 CMS
Novartis Pharmaceuticals Corporation $8.8910/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658919897 CMS
PFIZER INC. $2.7510/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673198405 CMS
PFIZER INC. $1.7710/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673198407 CMS
Medtronic USA, Inc. $14.6809/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 667736401 CMS
Janssen Biotech, Inc. $12.5709/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658307393 CMS
Janssen Biotech, Inc. $124.9909/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718859679 CMS
Incyte Corporation $125.0009/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666276245 CMS
E.R. Squibb & Sons, L.L.C. $10.1709/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300823 CMS
Novartis Pharmaceuticals Corporation $5.6409/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658919913 CMS
PFIZER INC. $3.1409/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673016655 CMS
PFIZER INC. $1.6809/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673017515 CMS
E.R. Squibb & Sons, L.L.C. $6.7109/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300821 CMS
Janssen Biotech, Inc. $16.3409/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658307389 CMS
TESARO, Inc. $87.8208/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675553859 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.1308/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697406101 CMS
E.R. Squibb & Sons, L.L.C. $10.1308/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300817 CMS
Incyte Corporation $5.5808/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666276183 CMS
Merck Sharp & Dohme Corporation $14.9208/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695717161 CMS
Genentech USA, Inc. $15.4208/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681406553 CMS
Novartis Pharmaceuticals Corporation $7.4108/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658919893 CMS
E.R. Squibb & Sons, L.L.C. $6.7008/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300815 CMS
Astellas Pharma US Inc $14.7808/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655448515 CMS
JAZZ PHARMACEUTICALS INC. $21.9408/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684177971 CMS
Genentech USA, Inc. $17.8607/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681415405 CMS
Janssen Biotech, Inc. $15.5707/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658307383 CMS
E.R. Squibb & Sons, L.L.C. $12.9907/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300809 CMS
Verastem, Inc. $88.8707/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699790571 CMS
E.R. Squibb & Sons, L.L.C. $14.0407/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300801 CMS
E.R. Squibb & Sons, L.L.C. $0.7207/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300803 CMS
E.R. Squibb & Sons, L.L.C. $7.1107/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651300811 CMS
AstraZeneca Pharmaceuticals LP $78.7006/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685555423 CMS
AbbVie, Inc. $18.4606/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647803717 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,364.35 107
PY2020 $526.62 12
PY2021 $133.09 3
PY2022 $360.12 5
PY2023 $966.65 21
PY2024 $783.98 11
PY2025 $663.11 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $813,810.23 86
PY2024 Principal investigator $353,805.35 318
PY2023 Principal investigator $781,091.71 185
PY2022 Principal investigator $668,992.46 76
PY2021 Principal investigator $746,317.94 121
PY2020 Principal investigator $559,338.29 124
PY2019 Recipient $1,341.00 1
PY2019 Principal investigator $441,514.52 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

76 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,511.97 12/31/2022 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
Trastuzumab deruxtecan with pertuzumab-matching placebo No dispute reported 06/30/2026 914597777
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,967.56 12/31/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
Trastuzumab deruxtecan with pertuzumab-matching placebo No dispute reported 06/30/2026 914601161
Principal investigator 1 Genentech, Inc. $17,396.00 12/21/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC No dispute reported 06/30/2026 950692435
Principal investigator 1 Genentech, Inc. $70,428.00 12/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 950692253
Principal investigator 1 Seagen Inc. $295.00 12/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856457
Principal investigator 1 Seagen Inc. $295.00 12/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856469
Principal investigator 1 Genentech, Inc. $10,583.00 12/14/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC No dispute reported 06/30/2026 950692441
Principal investigator 1 Genentech, Inc. $2,556.00 12/14/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC No dispute reported 06/30/2026 950692445
Principal investigator 1 GlaxoSmithKline, LLC. $1,398.00 12/12/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 965505303
Principal investigator 1 GlaxoSmithKline, LLC. $1,505.00 11/17/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 943950007
Principal investigator 1 GlaxoSmithKline, LLC. $8,500.00 11/03/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 943950001
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 11/02/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 943950005
Principal investigator 1 Genentech, Inc. $89,741.00 10/28/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC No dispute reported 06/30/2026 950704761
Principal investigator 1 ViiV Healthcare Company $1,125.00 10/26/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 943806653
Principal investigator 1 Genentech, Inc. $1,500.00 10/21/2022 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 950641271
Principal investigator 1 Genentech, Inc. $7,964.00 10/19/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC No dispute reported 06/30/2026 950704767
Principal investigator 1 Seagen Inc. $765.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 917856435
Principal investigator 1 Seagen Inc. $956.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856485
Principal investigator 1 ViiV Healthcare Company $7,000.00 10/14/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 943806647
Principal investigator 1 GlaxoSmithKline, LLC. $1,398.00 09/19/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 943949997
Principal investigator 1 F. Hoffmann-La Roche AG $1,500.00 09/16/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC No dispute reported 06/30/2026 950716477
Principal investigator 1 F. Hoffmann-La Roche AG $1,500.00 09/16/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC No dispute reported 06/30/2026 950716483
Principal investigator 1 Seagen Inc. $295.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856369
Principal investigator 1 SANOFI US SERVICES INC. $1,125.00 09/06/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935584757
Principal investigator 1 Genentech, Inc. $9,500.00 09/01/2022 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 950649271
Principal investigator 1 Genentech, Inc. $1,500.00 08/30/2022 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 950649725
Principal investigator 1 Genentech, Inc. $1,500.00 08/30/2022 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 950649763
Principal investigator 1 Genentech, Inc. $1,500.00 08/30/2022 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 950649793
Principal investigator 1 GlaxoSmithKline, LLC. $1,398.00 08/24/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 943950003
Principal investigator 1 Seagen Inc. $295.00 08/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856357
Principal investigator 1 GlaxoSmithKline, LLC. $1,398.00 08/02/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 943949999
Principal investigator 1 Seagen Inc. $765.00 07/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer No dispute reported 06/30/2026 917856319
Principal investigator 1 Seagen Inc. $295.00 07/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856351
Principal investigator 1 Seagen Inc. $956.00 07/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856411
Principal investigator 1 AstraZeneca Pharmaceuticals LP $26,104.25 07/08/2022 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
Trastuzumab deruxtecan with pertuzumab-matching placebo No dispute reported 06/30/2026 914590751
Principal investigator 1 GlaxoSmithKline, LLC. $2,796.00 06/28/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 943949995
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,500.00 06/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 914598889
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,000.00 06/15/2022 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 914599733
Principal investigator 1 Genentech, Inc. $52,190.25 06/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 950729297
Principal investigator 1 Seagen Inc. $295.00 05/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856093
Principal investigator 1 Seagen Inc. $1,841.00 05/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856101
Principal investigator 1 Seagen Inc. $1,280.00 05/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856107
Principal investigator 1 Seagen Inc. $2,000.00 05/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856111
Principal investigator 1 Seagen Inc. $295.00 05/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856255
Principal investigator 1 SANOFI US SERVICES INC. $1,125.00 05/03/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935582941
Principal investigator 1 Novartis Pharmaceuticals Corporation $970.00 04/15/2022 Non-covered Recipient Entity
CANCER CARE NETWORK S TEXAS
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB (BYL719) IN COMBINATION WITH NAB-PACLITAXEL IN PATIENTS WITH ADVANCED TRIPLE NEGATIVE BREAST CANCER WITH EITHER PHOSPHOINOSITIDE-3- No dispute reported 06/30/2026 909392905
Principal investigator 1 Seagen Inc. $295.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856071
Principal investigator 1 Seagen Inc. $2,150.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856081
Principal investigator 1 Seagen Inc. $295.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856197
Principal investigator 1 Seagen Inc. $295.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856213
Principal investigator 1 Seagen Inc. $956.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856219
Principal investigator 1 Seagen Inc. $295.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856225
Principal investigator 1 Seagen Inc. $295.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856231
Principal investigator 1 Seagen Inc. $3,430.00 03/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917855449
Principal investigator 1 Seagen Inc. $2,150.00 03/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856047
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,000.00 03/09/2022 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer No dispute reported 06/30/2026 914595107
Principal investigator 1 Seagen Inc. $8,990.00 03/07/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856277
Principal investigator 1 Seagen Inc. $8,990.00 03/07/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856301
Principal investigator 1 Genentech, Inc. $6,000.00 02/25/2022 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 950682571
Principal investigator 1 AstraZeneca Pharmaceuticals LP $38,332.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
Trastuzumab deruxtecan with pertuzumab-matching placebo No dispute reported 06/30/2026 914595419
Principal investigator 1 Seagen Inc. $2,150.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917855431
Principal investigator 1 SANOFI US SERVICES INC. $1,125.00 02/14/2022 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 935583399
Principal investigator 1 Seagen Inc. $8,990.00 02/14/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856271
Principal investigator 1 Seagen Inc. $8,990.00 02/14/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856295
Principal investigator 1 Seagen Inc. $8,990.00 01/31/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856265
Principal investigator 1 Seagen Inc. $8,990.00 01/31/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856289
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,928.43 01/28/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY
EPIK-B2: A TWO PART, PHASE III, MULTICENTER, RANDOMIZED (1:1), DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB (BYL719) IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH HER2-POSIT No dispute reported 06/30/2026 909418059
Principal investigator 1 Novartis Pharmaceuticals Corporation $112,449.00 01/19/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH
A PHASE II MULTICENTER OPEN LABEL TWO COHORT NON COMPARATIVE STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB PLUS FULVESTRANT OR LETROZOLE IN PATIENTS WITH PIK3CA MUTANT HORMONE RECEPTOR HR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER ABC WHO HAVE P No dispute reported 06/30/2026 909425937
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,400.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer No dispute reported 06/30/2026 914595003
Principal investigator 1 Eli Lilly and Company $15,514.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 917841625
Principal investigator 1 Eli Lilly and Company $3,824.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 917844105
Principal investigator 1 Seagen Inc. $2,150.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917855395
Principal investigator 1 Seagen Inc. $2,150.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917855489
Principal investigator 1 Seagen Inc. $956.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917855495
Principal investigator 1 Seagen Inc. $8,990.00 01/04/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856259
Principal investigator 1 Seagen Inc. $8,990.00 01/04/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917856283